ArticleScientific reports2025

Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy.

Josh Thomas Georgy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.